Close

Form 6-K GLAXOSMITHKLINE PLC For: Oct 01

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. SPY
5. INFY
6. SNV
7. TSLA
8. SMCI
9. SLB
10. PPG


October 1, 2015 11:40 AM EDT

FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
 
 


GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').

On 30 September 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £12.51 per Ordinary Share, and notional ADSs at a price of $37.86 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2015 to 30 September 2015:
 
Non Executive Director
Ordinary Shares
                                                                      No. of ADSs
     
Sir Philip Hampton
3,497.202
  
     
Professor Sir Roy Anderson
574.540
  
     
Dr Stephanie Burns
  
757.793
     
Stacey Cartwright
424.660
  
     
Lynn Elsenhans
  
1,552.170
     
Judy Lewent
  
587.943
     
Sir Deryck Maughan
  
1,829.157
     
Dr Daniel Podolsky
  
1,371.868
     
Urs Rohner
524.580
  
     
Hans Wijers
424.660
  
     

The Company and the Non-Executive Directors were informed of these allocations on 1 October 2015.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).


V A Whyte
Company Secretary

1 October 2015
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 01, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings